1型免疫反应与病毒感染影响哮喘的糖皮质激素反应
研究基于SARP-3队列,对哮喘患者痰液进行全转录组基因网络和病毒宏基因组分析,发现22%患者高表达T1网络基因、35%高表达T2网络基因、8.5%同时高表达两者。糖皮质激素强烈抑制T2但难以抑制T1基因表达,FEV1改善仅见于T1低/T2高患者,高病毒携带与T1高疾病风险增加14倍相关。
要点
- 哮喘中T1-high占22%,T2-high占35%,T1/T2双高占8.5%。
- 糖皮质激素强烈抑制T2但对T1抑制差,FEV1改善仅见于T1低/T2高患者。
- 24%痰样本检出呼吸道病毒,高病毒携带与T1-high风险增加14倍相关。
核心结论
- 气道T1免疫反应在哮喘中较常见,对糖皮质激素抵抗,与亚临床病毒感染相关。
研究设计与样本
- SARP-3队列患者基线、肌注曲安奈德后及1年和3年随访采集痰液,行全转录组基因网络和病毒宏基因组分析。
主要发现
- 22%和35%的哮喘患者分别高表达T1和T2网络基因,8.5%同时高表达两网络。
- T2-high哮喘严重度结局比T1-high差,T1-high/T2-high亚组最严重。
- 糖皮质激素强烈抑制T2但 poorly 抑制T1基因表达。
- FEV1改善仅见于T1-low/T2-high患者,不见于T1-high/T2-high患者。
- 24%哮喘痰样本呼吸道病毒检测阳性,高病毒携带与T1-high疾病风险增加14倍相关。
临床怎么用
- 对T1-high/T2-high哮喘患者,糖皮质激素可能难以改善FEV1,需考虑其他治疗策略。
- 哮喘患者痰病毒检测阳性提示T1-high可能,影响激素反应评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Corticosteroid-responsive type 2 (T2) inflammation underlies the T2-high asthma endotype. However, we hypothesized that type 1 (T1) inflammation, possibly related to viral infection, may also influence corticosteroid response. Objectives: To determine the frequency and within-patient variability of T1-high, T2-high, and T1/T2-high asthma endotypes and whether virally influenced T1-high disease influences corticosteroid response in asthma. Methods: Patients in SARP-3 (Severe Asthma Research Program-3) had sputum collected at baseline, after intramuscular (triamcinolone acetonide) corticosteroid treatment, and at 1- and 3-year follow-ups. Sputum cell RNA was used for whole-transcriptome gene network and viral metagenomic analyses. We then profiled patients as highly expressing T1 and/or T2 gene networks and established the influence of these endotypes on corticosteroid responsiveness and the likelihood of viral transcript detection in the airways. Measurements and Main Results: We found that 22% and 35% of patients with asthma highly expressed T1 and T2 network genes, respectively, and that 8.5% highly expressed both networks. Asthma severity outcomes were worse in T2-high compared with T1-high asthma and most severe in the T1-high/T2-high subgroup. Corticosteroid treatment strongly suppressed T2 but poorly suppressed T1 gene expression, and corticosteroid-associated improvements in FEV1 occurred only in patients with T1-low/T2-high disease and not in patients with T1-high/T2-high disease. Viral metagenomic analyses uncovered that 24% of asthma sputum samples tested positive for a respiratory virus, and high viral carriage was associated with 14-fold increased risk of T1-high disease. Conclusions: Airway T1 immune responses are relatively common in asthma, are largely corticosteroid resistant, and are associated with subclinical viral infection.
引用
- Fahy JV, Jackson ND, Sajuthi SP, et al. Type 1 Immune Responses Related to Viral Infection Influence Corticosteroid Response in Asthma. Am J Respir Crit Care Med. 2025. PMID: 39601762. doi:10.1164/rccm.202402-0403OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。